Literature DB >> 26244327

MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia.

Steven P Treon1, Lian Xu, Zachary Hunter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26244327     DOI： 10.1056/NEJMc1506192

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  72 in total

1.  CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.

Authors:  Josephine M Vos; Nickolas Tsakmaklis; Christopher J Patterson; Kirsten Meid; Jorge J Castillo; Philip Brodsky; Tomas Ganz; Steven T Pals; Marie José Kersten; Lian Xu; Guang Yang; Steven P Treon; Zachary R Hunter
Journal:  Haematologica       Date:  2017-08-10       Impact factor: 9.941

2.  Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79.

Authors:  Andrew L Deng; Yu Ri Kim; Emily A Lichtenstein; Owen A O'Connor; Changchun Deng
Journal:  Haematologica       Date:  2017-03-24       Impact factor: 9.941

3.  Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.

Authors:  C Baer; F Dicker; W Kern; T Haferlach; C Haferlach
Journal:  Leukemia       Date:  2016-11-14       Impact factor: 11.528

4.  Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.

Authors:  Zachary R Hunter; Lian Xu; Nickolas Tsakmaklis; Maria G Demos; Amanda Kofides; Cristina Jimenez; Gloria G Chan; Jiaji Chen; Xia Liu; Manit Munshi; Joshua Gustine; Kirsten Meid; Christopher J Patterson; Guang Yang; Toni Dubeau; Mehmet K Samur; Jorge J Castillo; Kenneth C Anderson; Nikhil C Munshi; Steven P Treon
Journal:  Blood Adv       Date:  2018-11-13

Review 5.  Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience.

Authors:  Jorge J Castillo; M Lia Palomba; Ranjana Advani; Steven P Treon
Journal:  Ther Adv Hematol       Date:  2016-06-13

Review 6.  Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.

Authors:  Saurabh Zanwar; Jithma Prasad Abeykoon; Prashant Kapoor
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

Review 7.  Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.

Authors:  Alexander Grunenberg; Christian Buske
Journal:  Dtsch Arztebl Int       Date:  2017-11-03       Impact factor: 5.594

8.  MYD88 mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4.

Authors:  Maria Luisa Guerrera; Nickolas Tsakmaklis; Lian Xu; Guang Yang; Maria Demos; Amanda Kofides; Gloria G Chan; Robert J Manning; Xia Liu; Jiaji G Chen; Manit Munshi; Christopher J Patterson; Jorge J Castillo; Toni Dubeau; Joshua Gustine; Ruben D Carrasco; Luca Arcaini; Marzia Varettoni; Mario Cazzola; Steven P Treon; Zachary R Hunter
Journal:  Haematologica       Date:  2018-03-29       Impact factor: 9.941

9.  CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.

Authors:  Joshua N Gustine; Lian Xu; Nicholas Tsakmaklis; Maria G Demos; Amanda Kofides; Jiaji G Chen; Xia Liu; Manit Munshi; Maria Luisa Guerrera; Gloria G Chan; Christopher J Patterson; Andrew Keezer; Kirsten Meid; Toni Dubeau; Guang Yang; Zachary R Hunter; Steven P Treon; Jorge J Castillo
Journal:  Blood Adv       Date:  2019-10-08

10.  Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.

Authors:  Monique C Minnema; Eva Kimby; Shirley D'Sa; Luc-Matthieu Fornecker; Stéphanie Poulain; Tom J Snijders; Efstathios Kastritis; Stéphane Kremer; Aikaterini Fitsiori; Laurence Simon; Frédéric Davi; Michael Lunn; Jorge J Castillo; Christopher J Patterson; Magali Le Garff-Tavernier; Myrto Costopoulos; Véronique Leblond; Marie-José Kersten; Meletios A Dimopoulos; Steven P Treon
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.